ALLURION TECHNOLOGIES INC (ALUR)
OTCHealth CareMedical - DevicesSnapshot 2026-09-04
$1.12+1.82%
Close 2026-09-04 · 1-day change
OTCHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · ALUR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -68.8% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 62.2% |
Growth built into the price is above our model estimate.
The price assumes 130.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of — · Company calendar date is not available
ALUR — officer change
Dated 2026-08-24
Director — Krishna Gupta: Two directors resigned simultaneously, resulting in a reduction of the board size from five to three members.
Why it matters: Regaining compliance is important. It helps keep the company's public listing and investor trust.
Supportive ifThe company meets NYSE listing rules and keeps its listing.
Worry ifThe company does not meet NYSE listing rules and may be delisted.
Why it matters: Stable leadership is important for the company. More changes might mean bigger problems.
Worry ifA new CEO is chosen within 60 days. This shows a smooth leadership change.
Less concerning ifNo new CEO is chosen within 60 days. This suggests ongoing problems.
Why it matters: Revenue trends show how well the sales strategy works and how much people want the product.
Watch forQuarterly revenue grows over 10% from the last quarter.
Also watch forQuarterly revenue falls again. This shows continued sales problems.
Why it matters: M&A activity may show plans for growth. Good revenue growth means successful integration.
Supportive ifQuarterly revenue shows an increase of at least 10% following the M&A activity.
Worry ifQuarterly revenue may keep falling or stay the same after the M&A activity.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$676 on $10,000 · ±6.8% | How much price usually moves either way. |
| Bad day | $1,396 loss on $10,000 · 14.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,087 loss on $10,000 · 90.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This split aims to help Allurion regain compliance with NYSE listing rules. Success could improve stock visibility and liquidity.
Supportive ifThe stock price stabilizes above $3.00 for at least 20 trading days post-split.
Worry ifThe stock price drops below $2.00 within 20 trading days after the split.
Why it matters: A new CEO could help stabilize management and guide the company in a good way.
Supportive ifA new CEO is appointed and publicly announced.
Worry ifIf no new CEO is named in six months, management instability will continue.
Why it matters: Revenue trends show how well Allurion's strategies work and how much people want its products.
Watch forQuarterly revenue is over $3.5M. This shows the company is recovering.
Also watch forQuarterly revenue falls below $2.5M, showing ongoing problems.
Why it matters: This split aims to help regain compliance with NYSE listing standards. Success could improve liquidity and visibility for Allurion.
Supportive ifAllurion's stock has traded above $1 on the NYSE for 20 days after the split.
Worry ifStock price remains below $1 for 20 consecutive trading days after the split.
Why it matters: Revenue trends will show if the reverse stock split helps the business.
Watch forQuarterly revenue shows growth above $3M after the reverse stock split.
Also watch forQuarterly revenue continues to decline below $3M after the reverse stock split.
Why it matters: The CEO leaving could change Allurion's plans and how it grows.
Watch forNew CEO appointed with a clear strategy to enhance growth and compliance.
Also watch forNo new CEO appointed within three months, leading to uncertainty in strategy.
Why it matters: FDA approval is crucial for Allurion's growth strategy. It could boost revenue and market presence.
Supportive ifThe FDA grants approval for the Allurion Gastric Balloon System.
Worry ifThe FDA does not approve or delays its decision.
Why it matters: This split is key for regaining compliance with NYSE listing rules. A successful split may improve stock visibility and liquidity.
Supportive ifThe reverse stock split is completed on June 18, 2026, and shares begin trading under the new symbol ALURD.
Worry ifThe reverse stock split does not occur as planned or faces delays.
Why it matters: Revenue trends will indicate the success of the re-listing strategy and product traction. A decline may signal ongoing challenges.
Watch forQ3 revenue shows growth from the $2.95M reported in Q2 2026.
Also watch forQ3 revenue declines further from the $2.95M reported in Q2 2026.
Why it matters: New leaders are important for direction and investor trust. Uncertainty may hurt stock.
Watch forA new CEO or key executive is appointed to lead the company.
Also watch forNo new leaders are chosen, which keeps uncertainty going.